Thomas R. Kosten, MD

Baylor College of Medicine, Houston, Texas

  • 9Articles
  • 33.1KReads
  • 2007–2025Active
  • 58Collaborators
  • 209Citations

About

Thomas R. Kosten, MD, affiliated with Baylor College of Medicine in Houston, Texas, has published extensively from 2007 to 2025 on topics including major depressive disorder, schizophrenia and schizoaffective disorders, neurology, and suicide. His work covers the safety and efficacy of esmethadone as a rapid antidepressant, neuroimaging studies of white matter abnormalities in first-episode schizophrenia, genetic associations with schizophrenia, and the clinical management of antipsychotic-induced side effects. He has also investigated suicide risk factors in psychiatric populations.

Publications

JCP
Reasons for Maintaining the Classification of Esmethadone as an Investigational Uncompetitive NMDAR Antagonist Rapid Antidepressant: Reply to Ferré and Michaelides
Letter to the Editor

Reasons for Maintaining the Classification of Esmethadone as an Investigational Uncompetitive NMDAR Antagonist Rapid Antidepressant: Reply to Ferré and Michaelides

September 8, 2025

The authors reply to Ferré and Michaelides’ letter commenting on their recent study of long-term esmethadone treatment in MDD.
, , , et al
JCP
Long-Term Safety and Efficacy of Esmethadone in MDD
Original Research

Long-Term Safety and Efficacy of Esmethadone in MDD

February 17, 2025

A durable improvement in MDD symptoms for up to 1 year was observed with esmethadone with high rates of response and remission.
, , , et al
JCP
Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants
Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

June 17, 2024

Although this trial of esmethadone did not meet its primary outcome, some secondary and post hoc outcomes were promising.
, , , et al
JCP
Suicide Risk in a National VA Sample
Original Research

Suicide Risk in a National VA Sample

June 6, 2022

Predicting suicide is difficult, as suicidal behavior is not linked solely to any single behavior or psychiatric diagnosis. This study compared risk of suicidal behavior among a transdiagnostic sample...
, , , et al
JCP
Original Research

Extensive White Matter Abnormalities and Clinical Symptoms in Drug-Naive Patients With First-Episode Schizophrenia: A Voxel-Based Diffusion Tensor Imaging Study

February 24, 2016

, , , et al
JCP
Original Research

The Type 2 Diabetes Mellitus Susceptibility Gene IGF2BP2 Is Associated With Schizophrenia in a Han Chinese Population

April 15, 2013

, , , et al
JCP
Article

Gender Differences in Never-Medicated First-Episode Schizophrenia and Medicated Chronic Schizophrenia Patients

July 15, 2012

, , , et al
JCP
Letter to the Editor

Aripiprazole Treatment of Risperidone-Induced Hyperprolactinemia

July 21, 2009

, , , et al
JCP
Original Research

Disrupted Antioxidant Enzyme Activity and Elevated Lipid Peroxidation Products in Schizophrenic Patients With Tardive Dyskinesia

May 15, 2007

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe